0001799191-22-000058.txt : 20221220
0001799191-22-000058.hdr.sgml : 20221220
20221220200711
ACCESSION NUMBER: 0001799191-22-000058
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221216
FILED AS OF DATE: 20221220
DATE AS OF CHANGE: 20221220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Miller Matthew P
CENTRAL INDEX KEY: 0001915822
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39248
FILM NUMBER: 221476313
MAIL ADDRESS:
STREET 1: C/O THE ONCOLOGY INSTITUTE OF HOPE
STREET 2: 18000 STUDEBAKER ROAD, SUITE 800
CITY: CERRITOS
STATE: CA
ZIP: 90703
FORMER NAME:
FORMER CONFORMED NAME: Miller Matthew Seth Porter
DATE OF NAME CHANGE: 20220308
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncology Institute, Inc.
CENTRAL INDEX KEY: 0001799191
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 18000 STUDEBAKER RD
STREET 2: SUITE 800
CITY: CERRITOS
STATE: CA
ZIP: 90703
BUSINESS PHONE: 562-735-3226
MAIL ADDRESS:
STREET 1: 18000 STUDEBAKER RD
STREET 2: SUITE 800
CITY: CERRITOS
STATE: CA
ZIP: 90703
FORMER COMPANY:
FORMER CONFORMED NAME: DFP HEALTHCARE ACQUISITIONS CORP.
DATE OF NAME CHANGE: 20200108
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2022-12-16
0
0001799191
Oncology Institute, Inc.
TOI
0001915822
Miller Matthew P
C/O THE ONCOLOGY INSTITUTE INC.
18000 STUDEBAKER RD, SUITE 800
CERRITOS
CA
90703
0
1
0
0
Chief Operating Officer
Common Stock
2022-12-16
4
P
0
73684
0.95
A
175325
D
The purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 577 shares, with the reporting persons sale of shares of common stock on November 15, 2022. The reporting person has paid to the Issuer the full amount of the profit realized in connection with the short-swing transaction, less transaction costs, calculated in accordance with Section 16(b).
By: Mark Hueppelsheuser For: Matt Miller
2022-12-20